List of Excipients in Branded Drug PREPIDIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	PREPIDIL	dinoprostone	0009-3359	SILICON DIOXIDE
Pharmacia & Upjohn Company LLC	PREPIDIL	dinoprostone	0009-3359	TRIACETIN

PREPIDIL Excipient Strategy and Commercial Opportunities for Dinoprostone Cervical Gel

Last updated: September 24, 2026

PREPIDIL is a dinoprostone 0.5 mg intracervical gel used for cervical ripening in pregnant patients at or near term. Its commercial opportunity is primarily a hospital-focused generic or authorized-generic product with equivalent drug delivery, sterile unit-dose packaging, and reliable supply. The principal formulation challenge is preserving dinoprostone potency in a low-dose, aqueous gel while maintaining syringeability, retention at the cervix, sterility, and controlled drug release.

What is PREPIDIL and how is it used?

PREPIDIL contains dinoprostone, the synthetic form of prostaglandin E2. Each prefilled applicator delivers 0.5 mg of dinoprostone in approximately 2.5 mL of cervical gel.[1]

Attribute	PREPIDIL profile
Active ingredient	Dinoprostone
Pharmacologic class	Prostaglandin E2
Dosage form	Intracervical gel
Strength	0.5 mg per approximately 2.5 mL
Route	Endocervical administration
Primary use	Cervical ripening before labor induction
Setting	Hospital obstetric unit
Regulatory pathway	FDA-approved prescription drug
Product type	Small-molecule drug, not a biologic
Commercial channel	Institutional and hospital purchasing

PREPIDIL is administered by a trained healthcare professional through a catheter placed in the endocervical canal. The product is not designed for retail self-administration. Commercial demand is therefore tied to labor-and-delivery volumes, hospital formularies, obstetric protocols, and supply reliability.

Dinoprostone products require close clinical monitoring because prostaglandin activity can cause uterine tachysystole, fetal distress, nausea, vomiting, diarrhea, fever, and other adverse effects. The label also places restrictions on use in patients with contraindications to vaginal delivery or prior cesarean delivery, among other conditions.[1]

What excipients are used in PREPIDIL?

The PREPIDIL formulation uses a viscous gel system containing colloidal silicon dioxide, ethanol, hydroxypropyl cellulose, and triacetin, according to the product labeling.[1]

Excipient	Likely formulation function	Commercial and technical relevance
Hydroxypropyl cellulose	Viscosity modifier and gel-structure agent	Controls retention, flow, and syringe extrusion
Colloidal silicon dioxide	Rheology modifier and suspending aid	Influences gel consistency and physical stability
Triacetin	Solvent and plasticizing component	Supports drug solubilization and formulation uniformity
Ethanol	Co-solvent	Affects solubility, evaporation, local tolerability, and microbial control

The formulation has a narrow performance window. A gel that is too fluid can leak from the cervix and reduce dose retention. A gel that is too viscous can increase administration force, interfere with catheter delivery, and create dose-delivery variability.

Excipient substitution is therefore possible in principle but commercially difficult. A generic applicant must demonstrate that the substitute formulation provides equivalent quality, performance, and clinical use characteristics. FDA review would focus on drug content, assay, impurities, viscosity, pH, microbial quality, sterility where applicable, syringe functionality, extractables and leachables, and container-closure integrity.

How should a PREPIDIL generic optimize its excipient system?

The strongest formulation strategy is usually a Q1/Q2-oriented approach that preserves the functional role of the reference-product excipients while improving manufacturability or supply resilience.

Hydroxypropyl cellulose strategy

Hydroxypropyl cellulose is central to viscosity control. Its substitution level, molecular-weight grade, hydration profile, and concentration can change:

• Extrusion force through the applicator
• Cervical retention time
• Drug distribution within the gel
• Sedimentation or phase separation
• Batch-to-batch rheology
• Mixing and filling performance

A supplier with multiple pharmaceutical grades can reduce supply risk. The manufacturer should qualify at least two sources or establish a validated alternate grade if the regulatory filing permits it.

Colloidal silicon dioxide strategy

Colloidal silicon dioxide can modify rheology and help maintain a uniform suspension or dispersion. Its surface area, moisture content, particle characteristics, and dispersion method can materially affect the final product.

The highest-value process controls include:

1. Controlled order of addition.
2. High-shear dispersion limits.
3. Defined hydration or equilibration time.
4. In-process viscosity testing.
5. Control of entrapped air before syringe filling.

Excessive shear can change gel structure, while inadequate dispersion can produce nonuniformity and inconsistent syringe performance.

Triacetin and ethanol strategy

Triacetin and ethanol influence the solvent environment for dinoprostone. Changes in the ratio of these components may affect potency, degradation, local tolerability, and drug release.

Ethanol content also creates manufacturing and packaging considerations. The process must control evaporation during compounding, holding, and filling. Container closure must limit solvent loss over shelf life. The applicant should evaluate:

• Ethanol concentration at release and through expiry
• Headspace composition
• Weight loss under accelerated storage
• Syringe-barrel compatibility
• Plunger and tip-seal performance
• Dinoprostone degradation products

Water and pH control

Even when not the principal differentiator, water quality and pH control are critical. Dinoprostone is susceptible to chemical degradation, and the final formulation must preserve potency throughout the labeled storage period.

A robust development program should establish:

• pH operating range
• Buffer capacity, if any
• Water-for-injection controls
• Oxygen exposure during manufacturing
• Light sensitivity
• Freeze-thaw limits
• Compatibility with sterilization or aseptic processing

What formulation patents protect PREPIDIL?

PREPIDIL is an old small-molecule product, and its commercial protection is more likely to depend on regulatory exclusivity history, formulation know-how, manufacturing controls, and product-specific approval requirements than on an active, broad patent estate.

The core active ingredient, dinoprostone, is long established. Basic protection for the molecule and the general use of prostaglandin E2 in obstetrics is no longer commercially meaningful for a modern generic-entry analysis. The relevant IP questions concern later patents covering:

• Gel composition
• Viscosity-control systems
• Applicator design
• Unit-dose packaging
• Stabilization of dinoprostone
• Manufacturing processes
• Specific cervical-ripening methods

No active formulation patent should be assumed solely from the existence of the PREPIDIL brand. A current Orange Book review and a jurisdiction-specific patent search are required to establish whether any listed patent remains relevant. The Orange Book is the controlling source for FDA-listed patents associated with an approved drug product.[2]

What patent strategy is available to a follow-on manufacturer?

A follow-on manufacturer may pursue one of four strategies:

Strategy	Commercial objective	Main risk
Reference-like formulation	Maximize similarity and simplify development	Dependence on difficult-to-source excipients
Reformulated gel	Improve retention, extrusion, or stability	Greater FDA comparability burden
New applicator presentation	Improve usability and reduce administration errors	Device and combination-product review
Hospital-use package	Improve storage, handling, and waste control	Limited differentiation if pricing is the only advantage

A new formulation or applicator could generate patentable subject matter, but patent value would depend on demonstrated technical effects. A claim directed only to routine excipient substitution is vulnerable to validity challenges. Stronger claims would link composition to measurable improvements in stability, dose uniformity, administration force, retention, or reduced product waste.

When does PREPIDIL lose exclusivity?

PREPIDIL’s principal market exclusivity is not expected to be a current barrier to generic development because dinoprostone and the product have been available for many years.

Exclusivity category	PREPIDIL assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the cervical-ripening indication
Pediatric exclusivity	No current commercial barrier expected
New clinical investigation exclusivity	No current barrier identified from the established indication
Patent exclusivity	Requires current Orange Book verification
Regulatory exclusivity today	No practical exclusivity barrier expected based on product age

The main business question is therefore not whether the molecule remains exclusive. It is whether a manufacturer can obtain approval with an economically viable sterile or controlled-quality gel, prefilled applicator, and hospital supply model.

What is the Orange Book status of PREPIDIL?

The FDA Orange Book should be checked for the current status of the PREPIDIL reference listed drug, associated patents, and any approved therapeutic equivalents.[2] The relevant product identifier is the PREPIDIL dinoprostone intracervical gel product associated with FDA NDA 018009 in historical FDA materials.[1]

Orange Book analysis should cover:

• Whether the reference drug is listed as currently marketed
• Whether the NDA has a discontinued-marketing designation
• Whether any patents are listed
• Whether therapeutic equivalents have approval
• Whether a generic applicant must rely on a Paragraph IV certification
• Whether a product-specific bioequivalence or clinical endpoint requirement applies

A discontinued-marketing designation does not necessarily mean the drug was withdrawn for safety or that FDA approval was revoked. It can reflect commercial discontinuation. The distinction matters because the reference product may remain usable for abbreviated approval purposes even when supply is limited, subject to FDA requirements.

How does a PREPIDIL generic obtain FDA approval?

A generic applicant would generally pursue an ANDA if the product can meet FDA requirements for an equivalent dosage form, route, strength, active ingredient, and performance profile. For a locally administered gel, the development package may require more than simple systemic pharmacokinetic comparison.

The likely evidence package would include:

• Pharmaceutical equivalence
• Assay and content uniformity
• Comparative impurity profile
• Viscosity and rheology
• pH and osmolality, where applicable
• In vitro release or drug-release characterization
• Microbiological quality
• Sterility or aseptic-process validation, depending on product classification
• Device and applicator performance
• Container-closure integrity
• Stability data
• Comparative local performance or other FDA-requested evidence

The applicant must also address labeling, administration instructions, warnings, storage, and pregnancy-related risk information. A product with a materially different excipient system may create additional clinical or CMC questions even if the active ingredient and strength are unchanged.

What Paragraph IV challenges could affect PREPIDIL?

A Paragraph IV certification would be relevant only if a patent is listed in the Orange Book and the ANDA applicant asserts that the patent is invalid, unenforceable, or not infringed. Given the age of PREPIDIL, the more likely scenarios are:

1. No current listed patent, allowing approval without a Paragraph IV dispute.
2. A late-listed formulation or device patent, requiring a patent certification analysis.
3. A method-of-use patent that does not cover the full proposed label.
4. A patent dispute involving a reformulated or relabeled product rather than the original gel.

Any Paragraph IV litigation would depend on the specific listed patent, certification, notice date, and reference-product status. No litigation conclusion should be drawn from the brand name alone.

What commercial opportunities exist for PREPIDIL excipients?

The excipient opportunity is more attractive in supply, quality, and delivery performance than in simple ingredient replacement.

Premium pharmaceutical-grade excipients

Potential suppliers can compete by offering:

• Consistent hydroxypropyl cellulose viscosity grades
• Low-bioburden or low-endotoxin excipients
• Controlled-moisture colloidal silicon dioxide
• High-purity triacetin
• Low-peroxide solvent systems
• Regulatory support packages
• Dual-source qualification
• Compendial and noncompendial impurity data

For a hospital product, a supplier that reduces batch failures or supports regulatory documentation can capture value even without a novel excipient.

Excipient premixes

A qualified premix containing the gel-structure components could reduce manufacturing complexity. The premix would need validated homogeneity, controlled moisture, defined mixing instructions, and a clear change-control framework.

This approach could appeal to contract manufacturers producing several obstetric gels or other low-volume sterile or unit-dose products.

Applicator and packaging systems

The greatest commercial differentiation may come from the delivery system rather than from the excipients. Opportunities include:

• Lower-force prefilled syringes
• Improved catheter geometry
• Reduced residual volume
• Clear dose-volume markings
• Tamper-evident packaging
• Better protection against ethanol loss
• Unit packaging optimized for hospital medication management

A delivery system that reduces waste and administration variability can support formulary adoption even when the active ingredient is generic.

How strong is the PREPIDIL patent estate?

The patent estate is likely weak as a barrier to generic entry because the product is mature and the active ingredient has a long history of use. Its practical protection is more likely to come from formulation complexity, manufacturing validation, regulatory execution, and institutional supply contracts.

Estate component	Relative barrier
Dinoprostone composition of matter	Low
Original cervical-ripening use	Low
Basic aqueous gel	Low to moderate
Specific excipient ratios	Depends on surviving claims
Applicator and packaging	Moderate if technically differentiated
Manufacturing know-how	Moderate and difficult to replicate quickly
Hospital contracts and supply reliability	Moderate commercial barrier
FDA product-specific development requirements	Moderate regulatory barrier

A follow-on company with an established sterile manufacturing network and hospital sales force would have a stronger position than an ingredient supplier entering the market without finished-dose capabilities.

Which companies could challenge PREPIDIL commercially?

The likely competitive set includes:

• Generic pharmaceutical manufacturers with topical or vaginal gel capabilities
• Companies producing prostaglandin or obstetric hospital products
• Contract development and manufacturing organizations with aseptic filling
• Manufacturers of prefilled syringes and catheterized delivery systems
• Suppliers of pharmaceutical cellulose and silica excipients

Competition would likely focus on price, shortage protection, product availability, applicator usability, and hospital contracting. The market is unlikely to support a large consumer brand because administration occurs under clinical supervision.

What generic launch scenarios exist?

Low-cost reference-like launch

This strategy uses a close formulation and conventional prefilled syringe. It has the shortest path to market but limited differentiation. Margin depends on manufacturing scale and hospital contract access.

Supply-reliability launch

The manufacturer positions the product around consistent availability, dual-sourced excipients, and dependable lead times. This can be valuable in obstetrics, where substitution during labor induction is operationally disruptive.

Premium delivery-system launch

A redesigned applicator reduces extrusion force, residual volume, or handling steps. This approach creates stronger commercial differentiation but may increase device-development and regulatory costs.

Hospital portfolio launch

The company sells PREPIDIL-equivalent dinoprostone alongside other labor-induction products, such as dinoprostone vaginal inserts or misoprostol products where approved and clinically appropriate. Portfolio selling can reduce customer-acquisition costs.

What licensing opportunities exist for PREPIDIL-related products?

Licensing opportunities are most credible in three areas:

1. A finished-dose product with FDA development work already completed.
2. A differentiated applicator or container-closure system.
3. A validated excipient platform that improves stability or administration performance.

A license structured around a basic excipient substitution would have limited value unless supported by freedom-to-operate analysis, comparative stability data, and a clear FDA filing path.

Potential deal structures include:

• Regional commercialization rights
• Supply-and-license agreements
• Contract manufacturing with minimum purchase commitments
• Co-development of a device-enabled product
• Exclusive hospital-channel distribution
• Dual-source supply agreements for critical excipients

What revenue exposure does PREPIDIL create?

Revenue potential is constrained by the narrow clinical use and hospital purchasing model. Demand is linked to:

• Annual births and labor-induction rates
• Hospital formulary placement
• Relative use of mechanical cervical-ripening methods
• Availability of competing dinoprostone dosage forms
• Use of misoprostol where clinically and institutionally accepted
• Generic price erosion
• Product shortages and supply continuity

The product can still be strategically valuable because it is a specialized, low-volume hospital product with limited room for casual substitution during administration. A manufacturer with efficient production and broad obstetric distribution can achieve attractive niche economics without requiring blockbuster sales.

Key Takeaways

• PREPIDIL is a 0.5 mg dinoprostone intracervical gel supplied in a prefilled applicator.
• Its key excipients are hydroxypropyl cellulose, colloidal silicon dioxide, triacetin, and ethanol.
• Excipient development should prioritize viscosity, syringeability, cervical retention, dinoprostone stability, and solvent-loss control.
• The molecule and original use are mature, so generic entry is more likely to face formulation and manufacturing barriers than meaningful composition-of-matter patent barriers.
• Current Orange Book patent status must control any Paragraph IV or launch analysis.
• The strongest commercial opportunity is a reliable hospital product with a close formulation, robust aseptic or controlled-quality manufacturing, and a differentiated applicator.
• Excipient suppliers can compete through pharmaceutical-grade consistency, dual sourcing, regulatory documentation, and premix or delivery-system integration.
• A licensing deal is most attractive when it includes an approved or near-approval finished product, a defensible delivery system, or validated stability improvements.

FAQs

Is PREPIDIL a biologic or a small-molecule drug?

PREPIDIL is a small-molecule drug containing dinoprostone, a synthetic prostaglandin E2 analogue. Biosimilar approval rules do not apply.

Can PREPIDIL be replaced by a different dinoprostone dosage form?

Not automatically. A cervical gel, vaginal insert, and other dinoprostone presentations differ in dose delivery, administration, release characteristics, labeling, and clinical use. Institutional substitution requires regulatory and formulary review.

Which PREPIDIL excipient is most important for product performance?

Hydroxypropyl cellulose is likely the principal viscosity-control excipient, but colloidal silicon dioxide, triacetin, ethanol, and processing conditions collectively determine gel performance.

Does a PREPIDIL generic require a Paragraph IV certification?

Only if the FDA Orange Book lists an unexpired patent for the reference product. If no relevant patent is listed, a Paragraph IV certification would not be required for that product.

Is there a biosimilar opportunity for dinoprostone?

No. Dinoprostone is a chemically synthesized small molecule, so a follow-on product would normally be evaluated through the generic-drug pathway rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). PREPIDIL (dinoprostone) intracervical gel prescribing information. FDA Drugs@FDA and product labeling records.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book